Compare
Propanc Biopharma, Inc. vs Nomad Power Solutions, Inc. vs NRX Pharmaceuticals, Inc. vs Imunon, Inc.
| Latest fiscal year | Propanc Biopharma, Inc. PPCB | Nomad Power Solutions, Inc. NMAD | NRX Pharmaceuticals, Inc. NRXP | Imunon, Inc. IMNN |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $1.45M | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | 65.1% (computed) | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$18.86M | -$6.08M | -$28.62M | -$14.50M |
| EPS (Diluted) | -$17.62 | -$1.26 | n/a | -$6.83 |
| Operating cash flow | -$5.68M | -$3.07M | -$14.11M | -$13.90M |
| Free cash flow | -$5.69M | n/a | n/a | -$14.18M |
| Cash & equivalents | n/a | n/a | $7.80M | $8.78M |
| Total assets | $12.78M | $12.73M | $12.96M | $12.29M |
| Total liabilities | $3.38M | $1.77M | $28.89M | $5.23M |
| Shareholders' equity | $9.40M | $9.66M | -$15.94M | $7.06M |
| Return on year-end equity | -200.6% | -62.9% | n/a | -205.3% |
| Shares outstanding | 3.31M | 8.79M | 31.73M | 3.42M |
Revenue, most recent five fiscal years
| Fiscal year | Propanc Biopharma, Inc. | Nomad Power Solutions, Inc. | NRX Pharmaceuticals, Inc. | Imunon, Inc. |
|---|---|---|---|---|
| Latest | n/a | $200.0K Ended 2015-12-31 | $1.45M Ended 2025-12-31 | $500.0K Ended 2022-12-31 |
| 1 year earlier | n/a | n/a | $0 Ended 2024-12-31 | $500.0K Ended 2021-12-31 |
| 2 years earlier | n/a | $0 Ended 2013-12-31 | $0 Ended 2023-12-31 | $500.0K Ended 2020-12-31 |
| 3 years earlier | n/a | $0 Ended 2012-12-31 | n/a | $500.0K Ended 2019-12-31 |
| 4 years earlier | n/a | $0 Ended 2011-12-31 | n/a | $500.0K Ended 2018-12-31 |